Orifarm, a Denmark-headquartered family-owned pharmaceutical company with leading positions across generics, prescription medicines, and over-the-counter healthcare products, is strengthening its focus on pharmaceuticals by divesting 16 long-established vitamins, minerals and supplements (VMS) brands to Stada, a Germany-based European consumer healthcare, generics, and specialty pharma company.
Orifarm is divesting the VMS portfolio in order to focus on pharmaceuticals through parallel traded medicine, niche generics, promotional prescription medicine, and over-the-counter medicine. The agreement with Stada supports Orifarm’s long-term strategic direction and focus on affordable medicine.
“The VMS portfolio . . . sits outside Orifarm’s long-term strategic focus: pharmaceuticals,” said Mads Fink Eriksen, CEO, Orifarm. “Divesting our VMS business allows us to focus on securing access to affordable medicine across Europe – our core capability and where we can make the biggest difference for our customers.”
The divested brands, among many others, include: the Nycoplus pharmacy VMS line in Norway; the Apovit VMS range in Danish pharmacies; popular Magnecaps magnesium-based supplements in Belgium; and the Vitrum VMS brand in Poland.
“We intend to invest further behind the strong heritage and consumer appeal of these leading brands, such as through adding innovative line extensions, to accelerate their current growth trajectory,” said Peter Goldschmidt, Stada CEO. “We will realise synergies with our existing Consumer Healthcare portfolios to the benefit of both consumers and pharmacists.”
The deal marks the first transaction conducted under Stada’s new majority ownership by private-equity investor CapVest. In September 2025, CapVest signed a definitive agreement to acquire a majority stake in Stada from Bain Capital and Cinven in a deal rumoured to be for around US$10bn.
It fits closely with Stada’s Consumer Healthcare strategy of focusing on local hero brands that hold leading positions in national or regional markets. The firm intends to increase the brands’ consumer appeal through all relevant retail channels, including online pharmacies.
Houlihan Lokey (Paul Tomasic, Gustaf Orsucci, Garyth Stone, Jorge Granados, Owen Richards, Szymon Stankowski and Felix Braun served as the exclusive sellside financial advisor to Orifarm.
Deloitte advised Orifarm on its divestment.
Press release: Orifarm divests VMS portfolio to STADA to sharpen focus on pharmaceuticals – Orifarm
